Twenty-one asymptomatic subjects (32%) were determined to be H. pylori positive by the 13 C-UBT.

TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical ...